Please login to the form below

Not currently logged in
Email:
Password:

Shionogi-ViiV

This page shows the latest Shionogi-ViiV news and features for those working in and with pharma, biotech and healthcare.

GSK shelves ViiV sale as it lays out growth strategy

GSK shelves ViiV sale as it lays out growth strategy

Shares in the company traded up in the decision to hang onto ViiV - partnered with Pfizer and Shionogi but with GSK owning an 80% stake - as well as bullish statements from ... underlying performance at ViiV, GSK has come to the sensible decision to

Latest news

  • ViiV bags US approval for HIV blockbuster-in-waiting ViiV bags US approval for HIV blockbuster-in-waiting

    Triumeq combines ViiV's antiretroviral stalwarts lamivudine and abacavir with its brand new integrase inhibitor Tivicay (dolutegravir), which was approved in the US last August and in Europe in January. ... ViiV is already riding high at the moment as it

  • Developing your patient-centric strategy Developing your patient-centric strategy

    the GSK, Pfizer and Shionogi joint venture - and Gilead, two companies with a strong or, in ViiV's case exclusive, presence in HIV/AIDS products. ... ViiV's CEO Dr Dominique Limet said then: “We have to get closer to those people who live with the virus

  • ViiV wins European approval for Tivicay ViiV wins European approval for Tivicay

    HIV treatment licensed in combination with other anti-retroviral drugs. ViiV Healthcare's potential blockbuster HIV treatment Tivicay (dolutegravir) has been approved by the European Commission. ... ViiV was formed as an HIV-focused joint

  • FDA clears Isentress formulation for infants with HIV FDA clears Isentress formulation for infants with HIV

    Tivicay (dolutegravir)  – a fellow integrase inhibitor developed by the GlaxoSmithKline/Pfizer/Shionogi joint venture ViiV Healthcare – was approved in the US in combination with other antiretroviral agents to treat patients aged

  • ViiV's Tivicay for HIV on course for EU approval ViiV's Tivicay for HIV on course for EU approval

    More positive news for GSK, Pfizer and Shionogi joint venture. ViiV Healthcare's new HIV treatment Tivicay has been recommended for approval in the EU, a few weeks after making a ... It is the first product launched by ViiV, which is an HIV-focused joint

More from news
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The first is the revised deal between ViiV Healthcare (the speciality HIV company formed by GSK and Pfizer in 2009) and Shionogi. ... Under the new agreement, ViiV Healthcare will acquire the exclusive global rights to the assets in the Shionogi-ViiV

  • Shionogi: an expanding commercial focus Shionogi: an expanding commercial focus

    The candidate the company is most excited about is the nce-daily HIV integrase inhibitor dolutegravir, which Shionogi is co-developing with the Pfizer and GlaxoSmithKline's ViiV Healthcare venture. ... Establishes Shionogi-GlaxoSmithKline joint venture

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    Healthcare - the GSK, Pfizer and Shionogi joint venture - and Gilead, two companies with a strong or, in ViiV’s case exclusive, presence in HIV/AIDS products. ... Nevertheless, it’s worth revisiting the announcement of ViiV’s birth four and a half

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics